ADVIK LABORATORIES LTD.

Advik Laboratories Ltd has announced that its Board of Directors will convene on September 2, 2026, at 3:00 PM IST at its corporate office in New Delhi. The primary agenda items include the consideration and approval of the notice for the Annual General Meeting (AGM) for FY 2025-26, the Director's Report, Management Discussion and Analysis Report, and Corporate Governance Report. Additionally, the board will fix the date, time, and venue for the upcoming AGM, appoint a scrutinizer, and determine the book closure and e-voting dates.

Advik Laboratories Ltd (now MPS Pharmaa Limited) announced its standalone unaudited financial results for the quarter ended June 30, 2026. The Board of Directors approved the results and the limited review report during a meeting held on August 13, 2026. The company operates in a single segment, pharmaceuticals formulations. Management is actively exploring market and business opportunities and is in discussions with prospective buyers to finalize new deals, expressing confidence in restarting business operations.

Advik Laboratories Ltd (now MPS Pharmaa Limited) announced its standalone un-audited financial results for the quarter ended June 30, 2026. The board meeting, held on August 13, 2026, approved these results and the accompanying limited review report. The company operates in a single segment, pharmaceuticals formulations. Management is actively seeking buyers and exploring new business opportunities to restart operations, with the belief that new deals will be finalized soon.

Advik Laboratories Ltd has announced that its Board of Directors will convene on August 13, 2026, at 12:00 PM at its corporate office in New Delhi. The primary agenda is to consider and approve the Un-Audited Financial Results for the quarter ended June 30, 2026, along with the Limited Review Report. Additionally, the board may discuss other business matters. In line with SEBI regulations and the company's insider trading code, the trading window for designated employees and their relatives remains closed until August 15, 2026, to prevent any potential misuse of information related to the financial results.

Advik Laboratories Ltd has reported its investor complaint status for the quarter ended June 30, 2026. As per SEBI regulations, the company stated that there were no pending investor complaints at the beginning of the quarter, no new complaints received during the quarter, and consequently, no unresolved complaints at the end of the quarter. This indicates a smooth operational period concerning investor grievances.

Advik Laboratories Ltd has announced the closure of its trading window for directors, promoters, KMPs, designated employees, and their immediate relatives. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's code of conduct. The window will remain shut from July 1, 2026, until 48 hours after the declaration of the company's unaudited financial results for the quarter ending June 30, 2026. The date for the board meeting to approve these results will be communicated separately.

MPS Pharmaa's Board of Directors approved the standalone audited financial results for the quarter and financial year ended March 31, 2026. The board also re-appointed M/s Sanghi & Co., Chartered Accountants, as the Internal Auditor for FY 2026-27. The company reported a total income of ₹3.56 Lacs for Q4 FY26 and ₹6.3 Lacs for FY26, with a basic EPS of (₹0.19) for Q4 FY26 and (₹0.53) for FY26. The audit report included qualifications regarding investment valuation and stalled capital work in progress. The company is actively working to restart business operations and address outstanding Annual Listing Fees, which led to BSE suspending trading of its scrip.

MPS Pharmaa Limited's Board approved its standalone audited financial results for the quarter and financial year ended March 31, 2026. For FY26, the company reported a total comprehensive loss of ₹101.22 Lacs, widening from ₹88.81 Lacs in FY25, with an EPS of (0.53). The auditors issued a modified opinion, citing inability to verify investments worth ₹53.80 Lacs and concerns over stalled Capital Work in Progress of ₹2.41 Crore. The company explained that investment share certificates were misplaced and construction was temporarily suspended. M/s Sanghi & Co. was re-appointed as Internal Auditor. The company's drug manufacturing license renewal is pending, and it is actively seeking to restart business operations. Trading of its shares on BSE remains suspended due to unpaid Annual Listing Fees since FY21-22, with limited trading allowed on a trade-for-trade basis.

Advik Laboratories Ltd has scheduled a Board of Directors meeting on May 28, 2026, to consider and approve the audited financial results for the quarter and financial year ended March 31, 2026. The board will also consider the appointment of M/s Sanghi & Co. as the Internal Auditor for FY 2026-27. The trading window remains closed until May 30, 2026.

MPS Pharmaa Limited, formerly Advik Laboratories Limited, has confirmed that it does not meet the criteria to be classified as a "Large Corporate" (LC) as of March 31, 2026. This declaration is made in accordance with SEBI Circular No. SEBI/HO/DDHS/P/CIR/2021/613 dated August 10, 2021, read with SEBI/HO/DDHS/DDHS-RACPOD1/P/CIR/2023/172 dated October 19, 2023, and SEBI/HO/DDHS CIR/P/2018/144 dated November 26, 2018. Consequently, the company is not subject to the specific disclosure and compliance requirements for Large Corporates concerning fund-raising through the issuance of debt securities.